Lapatinib in Combination With Vinorelbine (VITAL)

NCT01013740 PHASE2 COMPLETED Results posted

This is a randomized, parallel-arm, open-label, multi-centre, Phase II study to determine the efficacy and safety of lapatinib in combination with vinorelbine or capecitabine in women with ErbB2 overexpressing metastatic breast cancer (MBC) who have received no more than one chemotherapeutic regimen in the metastatic setting.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	COMPLETED
Enrolment	112
Start date	Wed Nov 25 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cancer

Interventions

• Vinorelbine
• Lapatinib
• Capecitabine

Countries

France, Italy, Greece, Serbia, Chile, Germany, Poland, Mexico, Bulgaria, Spain